크레오에스지
Financials
Valuation Metrics
크레오에스지's Market Cap is ₩489B. At end of 2025 it was ₩972B. Ranked #1726 of 2,405 in KR market (top 72%), #1045 of 1,627 on KOSDAQ (top 64%), #87 of 158 in Software & Services (top 55%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 48.95B KRW | KR#1,726/2,405 Sec#87/158 |
| Revenue | 11.91B KRW | KR#2,253/2,405 Sec#146/158 |
| Net Income | -3.18B KRW | KR—/2,405 Sec—/158 |
| Total Assets | 91.40B KRW | KR#1,849/2,405 Sec#72/158 |
| Net Assets | 47.55B KRW | KR#1,934/2,405 Sec#97/158 |
| Employees | 47 | KR#2,064/2,405 Sec#134/158 |
| Value | ||
| P/B | 1.03x | KR#1,556/2,405 Sec#91/158 |
| P/S | 4.11x | KR#2,109/2,405 Sec#140/158 |
| FCF Yield | -5.87% | KR—/2,405 Sec—/158 |
| Profitability | ||
| ROE | -6.68% | KR#1,848/2,405 Sec#119/158 |
| ROA | -3.47% | KR#1,854/2,405 Sec#116/158 |
| Op. Margin | -31.95% | KR#2,168/2,405 Sec#141/158 |
| Revenue Growth | 33.49% | KR#346/2,405 Sec#21/158 |
| Financial Health | ||
| Debt Ratio | 92.22% | KR#1,470/2,405 Sec#118/158 |
| Total Debt | 56.65B KRW | KR#962/2,405 Sec#19/158 |
| FCF | -2.87B KRW | KR#1,377/2,405 Sec#96/158 |
| Cash | 427.9M KRW | KR#2,355/2,405 Sec#155/158 |
| Current Ratio | 1.03x | KR#1,680/2,405 Sec#127/158 |
| Performance | ||
| 1Y Return | -29.97% | KR#1,379/2,405 Sec#67/158 |
| 1M Return | -27.29% | KR#2,156/2,405 Sec#144/158 |
| From 52W High | -80.74% | KR#2,300/2,405 Sec#152/158 |
| 1Y MDD | -79.37% | KR#2,261/2,405 Sec#148/158 |
| Trading | ||
| Volume | 18,209 shares | KR#1,544/2,405 Sec#86/158 |
| Trading Value | 45.3M KRW | KR#1,777/2,405 Sec#99/158 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/158 |
| Per Share | ||
| EPS | -160 KRW | KR—/2,405 Sec—/158 |
| BPS | 2,395 KRW | KR#1,987/2,405 Sec#121/158 |
Company Info
CreoSG, established in 1997 and KOSDAQ-listed in 2002, strengthened its solutions business through a 2005 merger and expanded real estate operations in 2024. The company has diversified its portfolio to include solutions for financial institutions, bio-business for infectious disease vaccine development, and real estate operation and rental management. Leveraging its experience in financial system implementation, it is expanding into manufacturing and service sectors. CreoSG also pursues vaccine research and development utilizing system migration and a universal new drug development platform. It is headquartered in Gangnam-gu, Seoul Metropolitan City.